Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma.
Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Cook J, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves W, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar SV, Kumar SK.
Charalampous C, et al. Among authors: dispenzieri a.
Blood Cancer J. 2023 Dec 11;13(1):183. doi: 10.1038/s41408-023-00957-w.
Blood Cancer J. 2023.
PMID: 38072941
Free PMC article.
No abstract available.